Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Marina Konopleva et al.|Cancer Discovery|2018Cited by 570
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell LymphomaPreetesh Jain, Michael Wang, Shuangtao Zhao et al.|Journal of Clinical Oncology|2021Cited by 82
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndromeKelly S. Chien, Guillermo Garcia‐Manero, Kunhwa Kim et al.|British Journal of Haematology|2021Cited by 64